J&J’s consumer group chair announces retirement
NEW BRUNSWICK, N.J. Johnson & Johnson on Thursday reported that Colleen Goggins, worldwide chairman of the company’s consumer group, has announced her retirement from the company effective March 1, 2011.
“Throughout her tenure, Colleen has demonstrated our commitment to our consumers and our people, and has made major contributions to our success,” stated Bill Weldon, J&J chairman and CEO. “We thank Colleen for her dedication and extraordinary service, and wish her all the best in the years to come.”
Goggins joined Johnson & Johnson in 1981, and became president of J&J Canada in 1992; president of Personal Products Co., U.S. in 1994; and president of J&J Consumer in 1995. She was promoted to company group chairman in 1998. Goggins assumed her current position as a member of the executive committee in June 2001.
Weldon acknowledged that Goggins is among the group of executives that have led the effort to formulate and implement the remediation plan regarding the quality issues at McNeil. “In light of Colleen’s decision to retire, I am pleased that we have a clear remediation plan in place, and we will work together to ensure a smooth transition of her responsibilities,” Weldon said.
Both Weldon and Goggins recently were invited to testify on those quality issues for a Sept. 30 hearing hosted by the House of Representatives’ Committee on Oversight and Government Reform.
House committee to hold hearing over J&J recall
WASHINGTON House Committee on Oversight and Government Reform chairman Ed Towns, D-N.Y., on Thursday announced that the committee will hold a hearing Sept. 30 at 10 a.m. to examine the circumstances surrounding Johnson & Johnson’s recall of more than 135 million bottles of infant and children’s medicines produced by Johnson & Johnson/McNeil Consumer Healthcare, including children’s Tylenol, infant’s Tylenol, children’s Motrin and children’s Benadryl.
The hearing also will examine the circumstances surrounding a “phantom recall” of a particular Motrin product, which became public as a result of the committee’s hearing on May 27.
“This is about the safety of trusted medication that our children and grandchildren use,” Towns stated. “The evidence we have uncovered since our first hearing is extremely troubling.”
Witnesses invited to testify include Bill Weldon, J&J chairman and CEO, and Colleen Goggins, J&J worldwide chairman, consumer group.
The hearing will be webcast on the committee’s website, Oversight.house.gov.
CBO: Generics saved $33 billion for Medicare Part D in 2007
WASHINGTON Generic drugs saved Medicare Part D beneficiaries and the program as a whole $33 billion in 2007, according to a new report by the nonpartisan Congressional Budget Office. The CBO expected another $14 billion in annual savings to accrue as many new generics enter the market through 2012.
The main lobby for pharmacy benefit managers said the report also showed the advantages of pharmacy benefit managers.
“Tools pioneered by pharmacy benefit managers — including encouraging the use of generic medications — have lowered costs and expanded access to prescription drugs for seniors in Medicare Part D,” Pharmaceutical Care Management Association president and CEO Mark Merritt said.
The generic drug industry lobby hailed the report as well. “This new CBO study is just one of a continued body of evidence proving that generics are a key cost-saving component of our healthcare system,” a statement by the Generic Pharmaceutical Association read.
According to the market research firm IMS Health, generic drugs accounted for nearly 75% of prescriptions dispensed in the United States, but for just more than 19% of dollars spent.